Thromboembolic complications in patients with chronic lymphoproliferative diseases


Significant percent of patients with malignancy develop thromboembolic event (TE) during the disease course and those patients usually have shorter overall survival time. This study defines types of malignant lymphoproliferative diseases as well as other factors with high impact on overall survival time.


We confirm findings of increased risk for TE in patients with agressive forms of lymphoma and chronic lymphocytic leukemia, but without the influence of gender or age, except in case of high grade non Hodgkin lymphoma where patients younger than 60 years of age have higher risk for TE with regard to patients with 60 years of age or older.

Author Comments

Dr. Srdjan Nikolovski, MD
Dr. Srdjan Nikolovski, MD
Clinical Center Serbia, University Children's Hospital, School of Medicine University of Belgrade
Research Associate
Clinical Research
Belgrade, Serbia | Yugoslavia
Although we confirmed some previously proven findings, the result emphasizing the influence of high grade non Hodgkin lymphoma patient's age on the risk for thromboembolic events is revolutionary, and certainly represent the basis for further investigations in that and other similar groups of malignant lymphoproliferative diseases.Dr. Srdjan Nikolovski, MD


Article Web Page

Analysis of incidence of thromboembolic complications in patients with chronic lymphoproliferative diseases

Medical Youth

An increased risk for thromboembolism in cancer patients has been observed in patients with solid tumours, whereas little data exist on malignant lymphoma.

The aim of this study is determination of the incidence of TE in patients with non Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and chronic lymphocytic leukemia (CLL) treated in our institution.

We reviewed medical records of patients with NHL, HL and CLL diagnosed according to the WHO classification and treated at our institution between january 2006. and december 2014.

A total of 1054 patients, 48.4% had highgrade NHL, 20.0% low-grade NHL, 14.5% HL, 7.1% other forms of lymphoma and 10.0% CLL. In group of lymphoma patients, 72 (6.8 %) had at least one TE. TE included deep vein thrombosis (38.9%), jugular vein thrombosis (12.5%), pulmonary embolism (11.1%), CNS thrombosis (6.9%), superficial vein thrombosis (2.8%), acute myocardial infarction (1.4%) and other (26.4%). In 49 patients thrombosis occurred during treatment or up to three months after therapy completion, whereas in 23 patients thrombosis was diagnosed prior to therapy. Patients with aggressive NHL and CLL had significantly higher incidence of TE (8.63%, 8.57%) compared to other types of lymphoma patients (p = 0.009). There is no statistical significance of impact of different types of lymphoproliferative diseases on increased risk for TE.

This study confirmed findings of some earlier studies of increased risk of thromboembolic events (TE) in patients with agressive forms of chronic lymphoproliferative diseasses, but there is no significantly impact of gender or age on that risk.

December 2015
87 Reads

Similar Publications